$599

FDA Lifts BMF-219 Clinical Hold; Abvance ABV 101 Virtual KOL Event

Two cardiometabolic-related news items have been observed: FDA lifted the clinical hold on Biomea Fusion’s clinical trials of BMF-219 in T2DM and T1DM (view press release; view webcast); and Abvance Therapeutics hosted a virtual KOL event for its ABV 101 asset (view webcast). Below, FENIX provides highlights and insights for the respective news items. 

About The Author

Matthew Maryniak

|
President of Fenix Group International

Matthew has been a thought leader in the high-growth therapeutic areas of diabetes and cardiovascular medicine since 2006, making regular attendance at large and small CV/met scientific meetings and an architect of novel methods for assessing market opportunities. He has over a decade of experience in leading CV/met consulting engagements, is a published author in PM360 and Diabetes Technology & Therapeutics, and has been quoted in The Pink Sheet on anti-thrombotics.

If you receive our email blasts, you already have an account.

Purchase Blast$599.00

You can read the article’s full content online after purchase.